Amicus Therapeutics Inc (LTS:0HF9)
$ 9.978 -0.0808 (-0.8%) Market Cap: 2.98 Bil Enterprise Value: 3.18 Bil PE Ratio: 0 PB Ratio: 16.66 GF Score: 81/100

Amicus Therapeutics Inc to Discuss the Preclinical Data Presented at ASGCT - Call Transcript

Apr 30, 2019 / 12:30PM GMT
Release Date Price: $13.62
Operator

Good day, ladies and gentlemen, and welcome to the Amicus Therapeutics Positive Preclinical Gene Therapy Data Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded. I would now like to turn the conference over to Sara Pellegrino, Vice President of Investor Relations and Corporate Communications. Ma'am, you may begin.

Sara Pellegrino
Amicus Therapeutics, Inc. - Senior Director of IR

Thank you, Shannon. Good morning, and welcome everyone to our conference call to discuss Amicus Therapeutics positive preclinical Pompe disease gene therapy data. Speaking on today's call we have John Crowley, Chairman and Chief Executive Officer; and Dr. Hung Do, Chief Science Officer. Also available to participate in the Q&A, we have Bradley Campbell, President and Chief Operating Officer; Daphne Quimi, Chief Financial Officer; Jay Barth; Chief Medical Officer; and Jeff Castelli, Chief Portfolio Officer and Head of Gene therapy.

On this call, as referenced on Slide 2, we may make forward-looking statements within the meaning of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot